the members of this family had the R32W variant in GJB3 in addition to changes in GJB2. The authors concluded that the R32W variant in GJB3 may contribute to the high frequency hearing impairment and to the manifestation of the skin disease present in some members of the family.
We have analysed the GJB3 gene in 153 individuals with hearing loss and we have found seven patients with the R32W variant (5%). We also analysed 46 control subjects with no obvious skin disorder or hearing impairment and we detected eight individuals with R32W (17%), suggesting that this variant is a polymorphism which is quite common in the Spanish population (7.5%). 3 DNA samples from family members of five of the seven unrelated deaf patients with R32W were available for study. Segregation analysis of R32W and deafness in these families showed no association between the variant and the hearing impairment. The analysis of GJB2 showed that two of these families also had mutation 35delG in some members. One family presented a congenital deaf member homozygous for 35delG, also carrying R32W. The mother of this patient was a carrier of both 35delG in GJB2 and R32W in GJB3 and showed normal hearing and absence of skin disease. In one dominant family with progressive hearing loss, for whom the causative gene has not been found, two deaf members had 35delG and R32W in heterozygosity, whilst another deaf subject had only the mutation 35delG, all suggesting that the association between R32W and 35delG is not the cause of hearing impairment. None of these members had obvious skin abnormalities.
These results on the frequency of R32W in patients and controls, and the segregation studies clearly indicate that, despite arginine 32 of GJB3 being strongly conserved across evolution, this variant is not the cause of deafness or a skin disease in our patients, even in association with mutations in patients GJB2. 
Reply to letter from N López-Bigas et al
In our paper we stated that we had also found R32W in an individual with no obvious skin disorder or hearing impairment. This and other published data also supports R32W being a low frequency coding polymorphism, which interestingly does affect an evolutionary conserved amino acid residue. However, we also speculated that R32W may contribute to the severity of hearing impairment and/or epidermal disease based on its segregation within a small family harbouring the D66H mutation in GJB2 and in the context of genetic background. For example, the individual with all three connexin variants had the most severe case of epidermal disease. The family data is too small to make any concrete conclusions regarding R32W. López-Bigas and colleagues also show that R32W on its own and, in addition, in association with 35delG (the common recessive deafness mutation) has no modifying effect with regard to hearing loss. They can make no conclusions regarding its contribution to the severity of epidermal disease as they did not investigate it on a Cx26 or Cx31 skin disease associated dominant mutation such as D66H or R75W in Cx26 or any of the EKV associated Cx31 mutations. In addition, the authors cannot state that R32W does not contribute to severity of deafness until they have analysed individuals with D66H or other dominant GJB2 mutations rather than 35delG. That is, R32W penetrance may still be genetic background dependent. However, it is also equally likely that R32W does not contribute to disease manifestation on any genetic background. 
